Professor of Virology at the University of Western Ontario, who is a globally renowned, first-generation researcher of molecular virology, and won the Presidential Award and the prestigious Ho-Am medical Prize, among many others for his contribution to virology.
We also connect with
Professor of Pharmacology and Medical Science at the Menzies Health Institute Queensland Griffith University. Deputy Director of Center for Gene and Cell Therapy at The City of Hope-Beckman Research Institute
1. Dr. Kang: As the founder of Sumagen, a company specializing in the development of new biopharmaceuticals, the vaccine platform you use is a livestock virus called the VSV (Vesicular Stomatitis Virus). Could you explain more about how it works and builds immunity effectively?
Dr. Morris: Traditional antivirals reduce symptoms and help people recover faster but your technology uses an RNA technology called siRNA. Please tell us how how this gene silencing technology works?
3. Dr. Kang: You're holding clinical trials of COVID-19 vaccines, and your technology has been found to be effective against the South African variants. How are you responding to the new variants including Delta?
4. Dr. Morris: What stage of development is your technology in at the moment, and how effective do you expect it to be?
Dr. Morris: How have you been responding to the surge of new variants such as Delta? Do these mutations affect the development of treatments for COVID-19?
3. Dr. Kang: Both the South Korean and Canadian governments are backing your research. What are your plans? What does your timeline look like?
Dr. Morris: What does your time frame look like? When will your treatment become available?
4. Dr. Kang: How scalable will the production of your COVID-19 vaccines be?
Dr. Morris: Much of the focus of national COVID response plans have been on inoculating their populations. While it is important to roll out vaccinations, it’s just as critical to develop effective treatments that will cure people who have fallen ill with the virus. What are hospitals mostly using at the moment, and how important is it to broaden treatments from antiviral drugs like Remdesivir to biologics based on monocolonial antibodies?
5. Dr. Kang: How can we ensure that the next time a new type of infectious disease occurs, we can increase our ability to quickly respond to it?